Single-cell RNAseq of a-PD-1 relapsing YUMM2.1 tumours subsequently treated with PARP14i in vivo

PD-1 signalling blockade is highly effective at restoring immune surveillance and treating melanoma. However, redundant immune homeostatic mechanisms driven by chronic IFN? signalling can lead to ongoing immune evasion and acquired resistance. PARP14 mediates IFN?-driven resistance, and prolongs responsiveness to PD-1 blockade in preclinical models. Here we present a single cell RNAseq of immune cells from a-PD-1 relapsing mouse tumours, following subsequent PARP14i treatments alone and in combination with a-PD-1. Our findings highlight a robust PARP14i gene signature associated with improved patient survival, suggesting its potential to enhance PD-1 blockade efficacy.